Trouvez les meilleures technologies du CNRS pour mener à bien votre projet d’innovation.
06.11.2018
Matériaux – Revêtements 07293-01
06.11.2018
Matériaux – Revêtements 10581-01
06.11.2018
Chimie 08758-01
06.11.2018
11127-01
06.11.2018
Environnement et Energie 11107-01
19.10.2018
Diagnostic médical 08504-01
Nous pouvons vous accompagner sur toute votre
démarche de transfert de technologies.
Grâce à notre expérience, nos réseaux et notre connaissance de l’écosystème de l’innovation nous vous accompagnons tout au long de votre projet.
02731-01
Galenic formulation, Residual antibiotic activity, Resistance, Digestive and intestinal tract
French patent application FR0956542 filed on September 23, 2009 and entitled « Forme galenique capable d’absorber de manière spécifique les molécules indésirables présentes dans le tube digestif »
Elias FATTAL
Franceline REYNAUD
Nicolas TSAPIS
Collaborative research, exclusive or non exclusive licenses
Laboratoire de Physico-Chimie, Pharmacotechnie, Biopharmacie (UMR 8612 CNRS), Chatenay Malabry, France, http://www.umr-cnrs8612.u-psud.fr/
After antibiotics administration, a fraction of the drug is not absorbed and follows its progression to the colon before elimination. Intestinal excretion of residual and active antibiotics has various deleterious consequences:
– Intestinal flora disturbance and perturbation of the resistance functions to exogenous bacteria colonisation,
– Selection of resistant micro-organisms to administered antibiotics, whose dissemination can constitute a resistance mechanisms source, in a context of multiresistance development of various human pathogenic species.
Accidental or deliberate ingestion of medicines or domestic substances also represents a situation where adsorption or inactivation of undesirable molecules in the digestive tract is crucial.
Therefore, there is a real need for new galenic forms allowing elimination by adsorption or inactivation of undesirable molecules in the gastrointestinal tract, and overcoming disadvantages and obstacles of existing forms.
The present invention relates to galenic formulations including particles capable of specifically adsorbing undesirable molecules in the digestive tract, these particles comprising a cationic polymer associated to a metallic ion. The invention also relates to the particles preparation process and use.
The formulations described in the invention can be administered in all oral forms, including capsules and are designed to specifically release the adsorbents at a specific site of the intestinal tract (small intestine, colon). The formulations can be administered before, during or after administration of an antibiotic.
The main application of this invention is the use for the manufacture of a drug, useful for the prevention or treatment of adverse effects related to an intestinal and/or colic flora imbalance, that may result from an antibiotherapy for example.
For further information, please contact us (Ref 02731-01)
25.11.2015
Santé / Thérapeutique 01310-01, 01310-02, 04666-01
16.09.2014
Santé / Thérapeutique 01741-01
04.10.2013
Santé / Thérapeutique 02212-01
06.11.2018
Matériaux – Revêtements 07293-01
06.11.2018
Matériaux – Revêtements 10581-01
06.11.2018
Chimie 08758-01
06.11.2018
11127-01
06.11.2018
Environnement et Energie 11107-01
19.10.2018
Diagnostic médical 08504-01